Delegation from UK Foreign, Commonwealth & Development Office Visited HitGen Release Time：2025-06-04

On May 28, Catherine West, Parliamentary Under-Secretary of State (Indo-Pacific) at the Foreign, Commonwealth and Development Office of the UK, and Anthony Preston, British Consul General in Chongqing, along with their delegation, visited HitGen Inc. (SSE: 688222.SH). Dr. Jin Li, Chairman and CEO of HitGen, accompanied them throughout the visit.

During a laboratory tour and meeting, Dr. Jin Li provided a comprehensive introduction to HitGen’s history, development strategy, business landscape, as well as the company’s future development plan. He highlighted the company’s core technology platforms and distinctive advantages in driving "original innovation of drug discovery". HitGen has established leading technology platforms for the DNA­encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, it is developing a DEL+AI+automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to further accelerate the discovery and optimization of preclinical candidate compounds.

Specifically, Dr. Jin Li introduced HitGen’s UK subsidiary Vernalis and its connections with the UK’s biopharmaceutical ecosystem. Both parties held in-depth discussions on leveraging the UK’s life sciences innovation environment to expand collaborations and jointly advance drug discovery.

Catherine West highly commended HitGen's achievements in drug discovery, stating: "The UK government places a high priority on the life sciences sector and is committed to providing an enabling environment of investment and collaboration for international innovators, including those from China." Consul General Anthony Preston expressed his anticipation for "more significant progress in innovative drug development made by HitGen and its British partners to benefit patients worldwide".

In the future, HitGen will continue upholding its commitment to openness and collaboration, deepen its global strategic presence and actively collaborate with partners worldwide to jointly promote the innovative drug research and development.